LMN-201 for Prevention of C. Difficile Infection Recurrence
Public ClinicalTrials.gov record NCT05330182. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Randomized, Double-blind, Placebo-controlled Study of LMN-201 for Prevention of C. Difficile Infection Recurrence
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a multisite study to evaluate the safety, tolerability, and efficacy of LMN-201 in participants recently diagnosed with CDI who are scheduled to receive or are receiving SOC antibiotic therapy against C. difficile.
Study identification
- NCT ID
- NCT05330182
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2, Phase 3
- Enrollment
- 375 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 29, 2024 (Actual)
- Primary completion
- Aug 31, 2026 (Actual)
- Completion
- Dec 1, 2026 (Estimated)
- Last update posted
- Oct 5, 2026
2024 – 2026
United States locations
- U.S. sites
- 15
- U.S. states
- 12
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Kaiser Permanente | Escondido | California | 90027 | — |
| Gastroenterology Center of Connecticut | Hamden | Connecticut | 06518 | — |
| University of South Florida | Tampa | Florida | 33606 | — |
| Metro Infectious Disease Consultants, LLC | Burr Ridge | Illinois | 60527 | — |
| Baptist Health Research | Lexington | Kentucky | 40503 | — |
| Henry Ford Health System | Detroit | Michigan | 48202 | — |
| University of Minnesota | Minneapolis | Minnesota | 55455 | — |
| Mayo Clinic - Rochester | Rochester | Minnesota | 55905 | — |
| Weill Cornell Medicine | New York | New York | 10021 | — |
| IMA Clinical Research | Mount Airy | North Carolina | 27030 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Clinical Alliance for Infectious Diseases - Infectious Diseases, LLC | Annandale | Virginia | 22003 | — |
| University of Virginia School of Medicine | Charlottesville | Virginia | 22903 | — |
| Kaiser Permanente-Mid Atlantic | Springfield | Virginia | 22015 | — |
| UW Health University Hospital | Madison | Wisconsin | 53792 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05330182, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 5, 2026 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05330182 live on ClinicalTrials.gov.